TLX Telix Pharmaceuticals Limited

QT37

NASDAQ·Healthcare·Biotechnology·Australia

Latest market price

9.10

-0.41-4.31%

Overview Short InterestFilings

TLXQT37Telix Pharmaceuticals Limited·NASDAQ

Overview Short InterestFilings

9.10-4.31%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

DNLI-1.97%$18.94 NRIX-1.18%$26.80 IDYA-2.83%$31.96 IRON-2.41%$80.84 DYN-2.05%$16.69 BEAM-5.58%$27.23 VRDN-0.52%$24.67 ELVN-1.84%$44.25

Snapshot

Index	—	P/E	91.00	EPS (ttm)	0.10	Insider Own	6.33%	Shs Outstand	328.09M	Perf Week	-0.55%

Market Cap	2.99B	Forward P/E	138.35	EPS next Y	0.07	Insider Trans	0.01%	Shs Float	273.58M	Perf Month	-15.11%

Enterprise Value	3.31B	PEG	1.21	EPS next Q	—			Short Float	0.13%	Perf Quarter	-9.18%

Income	33.00M	P/S	3.37	EPS this Y	—			Short Ratio	1.27	Perf Half Y	-19.18%

Sales	886.00M	P/B	6.13	EPS next Y	-45.84%	ROA	2.40%	Short Interest	352.94K	Perf YTD	21.50%

Book/sh	1.48	P/C	11.85	EPS next 5Y	75.05%	ROE	7.24%	52W High	13.11 -30.59%	Perf Year	-14.39%

Cash/sh	0.77	P/FCF	—	EPS past 3/5Y	—	ROIC	-0.61%	52W Low	6.28 44.90%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	106.89	Sales past 3/5Y	70.28% 175.25%	Gross Margin	52.14%	Volatility	1.75% 1.76%	Perf 5Y	—

Dividend TTM	—	EV/Sales	3.74	EPS Y/Y TTM	-7.61%	Oper. Margin	-0.78%	ATR (14)	0.42	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	1.85	Sales Y/Y TTM	-6.64%	Profit Margin	3.69%	RSI (14)	35.21	Recom	2.20

Dividend Gr. 3/5Y	—	Current Ratio	2.01	EPS Q/Q	—	SMA20	-11.49%	Beta	0.98	Target Price	18.00

Payout	0.00%	Debt/Eq	1.19	Sales Q/Q	34.08%	SMA50	-17.68%	Rel Volume	1.05	Prev Close	9.51

Employees	1,152	LT Debt/Eq	1.16	Earnings	Feb 19	SMA200	-8.13%	Avg Volume	325.14K	Price	9.10

IPO Date	Nov 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	—	Net Debt/EBITDA	10.58	Volume	341,761	Change	-4.31%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-16-26	Reiterated	RBC Capital		$17 → $18
Dec-15-25	Initiated	RBC Capital	Sector Perform	$17
Sep-23-25	Reiterated	UBS	Buy	$20
Sep-10-25	Reiterated	HC Wainwright & Co.	Buy	$20
Aug-28-25	Downgrade	JP Morgan	Overweight → Neutral

Latest News· Times ET

Oct-27-26

Oct-27-2607:14PM

3 Australian Insider Backed Growth Stocks To Own In October 2026Yahoo

Oct-23-26

Oct-23-2604:13AM

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Caseseekingalpha.com

Oct-21-26

Oct-21-2608:13AM

Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat EarningsBenzinga

Oct-20-26

Oct-20-2606:10PM

Telix Reports Third Quarter 2026 Financial Performanceglobenewswire.com

Oct-19-26

Oct-19-2601:30AM

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.globenewswire.com

01:30AM

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telixglobenewswire.com

Oct-14-26

Oct-14-2601:00AM

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANMYahoo

Oct-09-26

Oct-09-2607:45AM

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Careglobenewswire.com

03:47AM

Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane AntigenBenzinga

Oct-06-26

Oct-06-2606:30AM

First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)globenewswire.com

Oct-01-26

Oct-01-2601:00AM

IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®globenewswire.com

Sep-30-26

Sep-30-2610:56AM

Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Tradezacks.com

06:21AM

Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume – What’s Next?defenseworld.net

05:38AM

Telix Receives FDA's Fast Track Designation For Its BiPASS Program To Trace Prostate Cancer Prior To BiopsyBenzinga

Sep-23-26

Sep-23-2608:13AM

Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In FocusYahoo

Company

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	886	790	783	503	—	—	—	—	—
Cost of Goods Sold Incl. D&A	424	370	274	188	—	—	—	—	—
Gross Profit	462	419	510	314	—	—	—	—	—
Selling, General and Administrative Excl. Other	257	234	207	134	—	—	—	—	—
Research and Development	212	168	121	129	—	—	—	—	—
Other Operating Expense	0	0	100	0	—	—	—	—	—
Operating Income	-8	17	82	16	—	—	—	—	—
Interest Expense	13	36	21	9	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	49	13	-5	-4	—	—	—	—	—
Net Income Before Taxes	29	-5	56	3	—	—	—	—	—
Income Taxes	-5	2	6	-2	—	—	—	—	—
Consolidated Net Income	33	-7	50	5	—	—	—	—	—
Net Income From Continuing Operations	33	-7	50	5	—	—	—	—	—
Net Income	33	-7	50	5	—	—	—	—	—
EPS (Recurring)	0.10	-0.02	0.15	0.02	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.10	-0.02	0.15	0.02	—	—	—	—	—
EPS (Diluted)	0.10	-0.02	0.14	0.02	—	—	—	—	—
EBITDA	31	52	101	23	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	91.00	—	110.00	—	—	—	—	—	—
Price To Sales Ratio	3.48	3.20	6.51	—	—	—	—	—	—
Gross Margin	52.14	53.04	65.13	62.43	—	—	—	—	—
Operating Margin	-0.90	2.15	10.47	3.18	—	—	—	—	—
Net Margin	3.72	-0.89	6.39	0.99	—	—	—	—	—
Shares Outstanding	339	338	331	319	—	—	—	—	—
Market Capitalization	3,085	2,532	5,097	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Darren Charlton	Group Chief Financial Officer	Sep 07 '26	Buy	9.66	2,071	19,998	13,992	Sep 14
Behrenbruch Christian	MD & Group CEO	Apr 29 '26	Buy	14.87	33,435	497,178	20,742,935	May 06
Behrenbruch Christian	MD & Group CEO	Apr 28 '26	Buy	14.48	34,500	499,560	20,709,500	May 06
Smith Darren Charlton	Group Chief Financial Officer	Mar 29 '26	Option Exercise	0.00	1,111	0	11,921	Apr 01

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.